Truist Financial Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target boosted by Truist Financial from $459.00 to $535.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price objective indicates a potential upside of 11.07% from the stock’s previous close.

A number of other research firms also recently issued reports on ALNY. UBS Group boosted their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Stifel Nicolaus boosted their price target on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a “buy” rating in a research note on Monday, October 6th. The Goldman Sachs Group upped their price objective on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a report on Tuesday, September 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Barclays boosted their target price on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Twenty-four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $463.08.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $481.67 on Friday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $492.62. The stock’s 50 day moving average is $455.90 and its 200 day moving average is $352.79. The firm has a market cap of $63.14 billion, a P/E ratio of -195.01 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company’s quarterly revenue was up 17.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,924 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the transaction, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,568,138.45. This trade represents a 12.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total value of $8,416,800.00. Following the sale, the director directly owned 775 shares of the company’s stock, valued at $362,390. The trade was a 95.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,144 shares of company stock valued at $44,160,261 over the last three months. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in the business. OFI Invest Asset Management boosted its holdings in shares of Alnylam Pharmaceuticals by 5.8% in the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 22 shares during the last quarter. Evelyn Partners Investment Management LLP raised its position in Alnylam Pharmaceuticals by 11.5% in the second quarter. Evelyn Partners Investment Management LLP now owns 290 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 30 shares during the period. Daiwa Securities Group Inc. boosted its stake in Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares during the last quarter. Sowell Financial Services LLC boosted its stake in Alnylam Pharmaceuticals by 6.2% in the third quarter. Sowell Financial Services LLC now owns 654 shares of the biopharmaceutical company’s stock valued at $298,000 after acquiring an additional 38 shares during the last quarter. Finally, Bayforest Capital Ltd grew its position in shares of Alnylam Pharmaceuticals by 14.6% during the 1st quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 39 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.